TY - JOUR
T1 - The association of COVID-19 vaccine availability with mental health among adults in the United States
AU - Shen, Chan
AU - Rashiwala, Lucy
AU - Wiener, R. Constance
AU - Findley, Patricia A.
AU - Wang, Hao
AU - Sambamoorthi, Usha
N1 - Funding Information:
This project described was supported in part by the National Institute of General Medical Sciences, 5U54GM104942-05 (RW) and by the National Institutes of Health (NIH) Agreement No. 1OT2OD032581-01 (US) and NIH/1OT2HL158258-01 (US), and the National Institute on Minority Health and Health Disparities through the Texas Center for Health Disparities (NIMHD), 5U54MD006882-10 (HW and US).
Publisher Copyright:
Copyright © 2022 Shen, Rashiwala, Wiener, Findley, Wang and Sambamoorthi.
PY - 2022/8/9
Y1 - 2022/8/9
N2 - Objective: To assess whether COVID-19 vaccine approval and availability was associated with reduction in the prevalence of depression and anxiety among adults in the United States. Methods: We adopted cross sectional and quasi-experimental design with mental health measurements before vaccine availability (June 2020, N = 68,009) and after vaccine availability (March 2021, N = 63,932) using data from Census Pulse Survey. Depression and anxiety were derived from PHQ-2 and GAD-2 questionnaires. We compared rates of depression and anxiety between June 2020 and March 2021. Unadjusted and adjusted analysis with replicate weights were conducted. Results: Depression prevalence was 25.0% in June 2020 and 24.6% in March 2021; anxiety prevalence was 31.7% in June 2020 and 30.0% in March 2021 in the sample. In adjusted analysis, there were no significant differences in likelihood of depression and anxiety between June 2020 and March 2021. Conclusion: Depression and anxiety were not significantly different between June 2020 and March 2021, which suggests that the pandemic effect continues to persist even with widespread availability of vaccines.
AB - Objective: To assess whether COVID-19 vaccine approval and availability was associated with reduction in the prevalence of depression and anxiety among adults in the United States. Methods: We adopted cross sectional and quasi-experimental design with mental health measurements before vaccine availability (June 2020, N = 68,009) and after vaccine availability (March 2021, N = 63,932) using data from Census Pulse Survey. Depression and anxiety were derived from PHQ-2 and GAD-2 questionnaires. We compared rates of depression and anxiety between June 2020 and March 2021. Unadjusted and adjusted analysis with replicate weights were conducted. Results: Depression prevalence was 25.0% in June 2020 and 24.6% in March 2021; anxiety prevalence was 31.7% in June 2020 and 30.0% in March 2021 in the sample. In adjusted analysis, there were no significant differences in likelihood of depression and anxiety between June 2020 and March 2021. Conclusion: Depression and anxiety were not significantly different between June 2020 and March 2021, which suggests that the pandemic effect continues to persist even with widespread availability of vaccines.
KW - COVID-19
KW - Census pulse survey
KW - anxiety
KW - depression
KW - vaccine availability
UR - http://www.scopus.com/inward/record.url?scp=85136850990&partnerID=8YFLogxK
U2 - 10.3389/fpsyt.2022.970007
DO - 10.3389/fpsyt.2022.970007
M3 - Article
AN - SCOPUS:85136850990
SN - 1664-0640
VL - 13
JO - Frontiers in Psychiatry
JF - Frontiers in Psychiatry
M1 - 970007
ER -